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CASE REPORT Open Access
Calcitonin gene related peptide
monoclonal antibody treats headache in
patients with active idiopathic intracranial
hypertension
Andreas Yiangou1,2,3, James L. Mitchell1,2,3, Vivek Vijay1,2,3, Olivia Grech1,2,3, Edward Bilton4, Gareth G. Lavery1,2,3,
Claire Fisher3, Julie Edwards3, Susan P. Mollan4 and Alexandra J. Sinclair1,2,3*
Abstract
Background: Headache is the dominant factor for quality of life related disability in idiopathic intracranial
hypertension (IIH) and typically has migraine-like characteristics. There are currently no evidence-based therapeutics
for headache in IIH, and consequently this is an important unmet clinical need.
Case series: We report a series of seven patients in whom headaches were the presenting feature of IIH and the
headaches had migraine-like characteristics, as is typical in many IIH patients. Papilloedema settled (ocular
remission) but headaches continued. These headaches responded markedly to erenumab, a monoclonal antibody
targeted against the calcitonin gene related peptide (CGRP) receptor. Of note, there was a recurrence of raised ICP,
as evidenced by a return of the papilloedema, however the headaches did not recur whilst treated with erenumab.
Conclusions: Those with prior IIH who have their headaches successfully treated with CGRP therapy, should remain
under close ocular surveillance (particularly when weight gain is evident) as papilloedema can re-occur in the
absence of headache. These cases may suggest that CGRP could be a mechanistic driver for headache in patients
with active IIH.
Keywords: CGRP monoclonal antibody, Headache, Idiopathic intracranial hypertension, Papilloedema, Raised
intracranial pressure
Introduction
Idiopathic intracranial hypertension (IIH) is a chronic
debilitating disease characterised by raised intracranial
pressure (ICP) that typically occurs in young, obese
women [1]. There is evidence of rapidly increasing inci-
dence (350% increase in 10 years), in line with global
obesity trends [1, 2]. Disability in IIH is predominantly
driven by debilitating headache [3]. Headaches in IIH
most frequently have migraine-like characteristics [4].
Therapeutic strategies to prevent headache in IIH are an
unmet need [1, 4, 5].
We report seven patients who presented with head-
aches in the setting of raised ICP and who met the diag-
nostic criteria for IIH [6], whose IIH remitted and
headaches persisted. Following trials of conventional
headache therapies that failed to control their headache
symptoms over 12 months, they were subsequently
treated with a monoclonal antibody targeted against
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calcitonin gene related peptide (CGRP) receptor, erenu-
mab (Aimovig®, Novartis). We discuss the possible
pathophysiological implications, and importantly the
clinical considerations. These cases may suggest a role of
CGRP in headache attributed to IIH. Importantly these
cases suggest that when headaches attributed to IIH are
controlled with medical therapy, ocular examinations
should continue to ensure papilloedema (optic disc
swelling secondary to raised ICP) does not recur silently.
Findings
Following IIH diagnosis all patients were treated accord-
ing to the IIH consensus guidelines with weight manage-
ment advice and acetazolamide therapy where
appropriate [1, 7]. The mean (SD) duration since the IIH
diagnosis was 2.4 years (1.5). All cases presented with in-
creased headaches at the time of initially elevated ICP
and IIH diagnosis. Their headaches persisted, even after
resolution of papilloedema, and had migraine-like char-
acteristics (photophobia, phonophobia, kinesophobia,
nausea and throbbing pain) as is typically reported in IIH
headache [1, 4, 6]. All patients were adult, female with
IIH in occular remission and chronic moderate/severe
headaches (≥15 per month) that ≥3 prior conventional
oral preventative treatments had failed (inadequate effi-
cacy with appropriate dosing and treatment duration; in-
tolerable adverse effects; contraindications preventing
use [8]) and then suffered recurrence of papilloedema
whilst on erenumab. In this cohort treatments that failed
included tricyclic antidepressants, topiramate, propran-
olol, pizotifen, duloxetine, dosulepin and candesartan.
These chronic migraine-like headaches were elibigle for
treatment with the CGRP monoclonal antibody erenu-
mab (Aimovig®, Novartis) within the National Health
Service (NHS) headache service at University Hospital
Birmingham NHS Foundation Trust, UK as part of a
free of charge scheme (Novartis).
The pathway for erenumab delivery entailed a full
headache and neuro-ophthalmology assessment prior to
erenumab initiation, including optical coherence tomo-
graphy (OCT) imaging and dilated slit lamp fundus
assessment, which confirmed complete resolution of
papilloedema (Table 1). Patients were then commenced
on erenumab 70 mg four-weekly subcutaneous injection
after a 30-day pre-treatment period including headache
diary evaluation. In all cases the headache response (im-
provement in monthly headache days and/ or severity)
was greater than 30% but less than 50% and hence, as
per the local pathway, the dose was increased to 140 mg
at 3 months. Patients were seen 3-monthly over a 12-
month period. Erenumab initiation (after assessment of
a 30-day pre-treatment period) and follow-up visits in-
volved headache diary evaluation of monthly moderate/
severe headache days (MmsHD) (moderate to severe
headaches lasting > 4 h), all monthly headache days
(MHD) (headaches of any severity lasting > 30min),
monthly analgesic frequency, headache severity, disabil-
ity (Headache Impact Test − 6, HIT-6) and IIH symp-
toms (Table 1). All patients had a stable course and
substantial history of debilitating migrainous headaches
prior to treatment initiation evident from the high bur-
den of monthly headache days 12 months prior to treat-
ment (Table 1).
Case 1
A 42 year old woman first presented with severe in-
creased headaches with visual obscurations, double vi-
sion, tinnitus and was noted to have papilloedema. The
headaches had migraine-like characteristics. She had a
past history of occasional episodic migraines, asthma
and fibromyalgia and a family history of migraines. Her
body mass index (BMI) was 33 kg/m2 and her LP open-
ing pressure was 34 cm CSF with no alternative cause of
raised ICP on brain imaging (MRI Head and MR Veno-
gram). A diagnosis of IIH was made [6] and she was
commenced on acetazolamide (later stopped due to side
effects) and advised to lose weight. The papilloedema re-
solved but debilitating headaches continued over the
subsequent 12 months. Therapeutic trials of topiramate,
amitriptyline and propranolol failed (pizotifen was con-
traindicated) and she was then commenced on erenu-
mab. Headaches substantially improved (Table 2) but
she developed worsening of her visual disturbances simi-
lar to that experienced at presentation and on review
was noted to have a papilloedema relapse (her BMI had
also increased) (Table 2). An LP revealed an opening
pressure of 31 cm CSF (followed by post-LP headache
exacerbation for 1 week) and she was commenced on ac-
etazolamide and advised to lose weight with subsequent
improvement of papilloedema. Her headaches remained
controlled throughout the following year despite the
relapse of IIH (Table 2).
Case 2
A 34 year old woman initially presented with increased
debilitating headaches, blurred vision, visual obscura-
tions, tinnitus and was noted to have papilloedema by
the optometrist. The headaches had migraine-like char-
acteristics. She had a past history of episodic migraine
but no family history of migraines. Her BMI was at 49
kg/m2 (reported weight gain of 30 kg over the preceding
5 years). After normal neuro-imaging, CT Head and CT
Venogram (apart from radiological signs of raised ICP),
she had an LP opening pressure of 34 cm CSF. A diag-
nosis of IIH was confirmed [6] and she was commenced
on acetazolamide and advised to lose weight. She devel-
oped side effects from acetazolamide, this was discontin-
ued. Therapeutic trials of topiramate and amitriptyline
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failed (beta blockers and pizotifen were contraindicated)
and her chronic headaches remained. Following weight
loss her papilloedema resolved but migraine-like head-
aches persisted with similar frequency and severity for
over 12 months and she was subsequently commenced
on erenumab. Headaches then substantially improved
(Table 2). During follow-up she reported weight gain
and symptoms of visual disturbances. She was noted to
have a papilloedema relapse (Fig. 1). She was offered
acetazolamide but declined and a referral to a commu-
nity weight management program was made. Following
further weight gain, after gall bladder surgery, her
papilloedema further worsened and she underwent
ventriculo-peritoneal shunt surgery to preserve vision.
Her headaches since erenumab initiation remained
improved despite the IIH relapse and shunt surgery.
Case 3
A 46 year old woman presented with substantially in-
creased headache symptoms, with migraine-like character-
istics, and was noted to have papilloedema. She had a past
history of episodic migraine for 20 years, depression but
no known family history of migraine. Her BMI was 39 kg/
m2 and no alternative cause of raised ICP on brain im-
aging (MRI Head and MR Venogram). LP recorded an
opening pressure of 36cmCSF and a diagnosis of IIH was
made [6]. She was offered acetazolamide and advised to
lose weight. Following weight loss, papilloedema resolved
but her chronic migraine-like headaches remained con-
sistently severe for at least 12months (Table 2). Head-
aches did not improve with a therapeutic trial of
amitriptyline. Other preventative therapies were contrain-
dicated (topiramate and beta-blockers due to severe
Table 1 Patient characteristics at erenumab initiation
P1 P2 P3 P4 P5 P6 P7 Mean
(SD)
Age (years) 42 34 46 24 36 25 25 33.1 (8.2)
Duration of IIH (years) 2 2 1 1 4 2 5 2.4 (1.5)
Headache exacerbation at IIH diagnosis +++ +++ +++ +++ +++ +++ +++
Duration of headaches from resolution of papilloedema to initiation of erenumab
(months)
12 3 3 3 24 6 3 7.7 (7.9)
Preventative drug class failure a 4 3 3 4 5 4 3 3.7 (0.8)
Preventative drug class trial b 3 2 1 0 4 1 1 1.7 (1.4)
Migraine family history yes no missing no no yes no
Migraine prior to IIH yes yes yes no no yes no
MmsHD 12months prior 12 20 16 16 14 8 14 14.3 (3.5)
p = 0.778
MmsHD at erenumab initiation 13 17 15 20 14 11 12 14.6 (3.1)
MHD 12months prior 30 30 30 30 28 30 20 28.3 (3.7)
p = 0.593
MHD at erenumab initiation 30 30 27 30 30 30 25 28.9 (2.0)
Headache severity (NRS) at erenumab initiation 5.7 5.2 7.2 7.3 5.2 4.5 7.1 6.0 (1.2)
Monthly analgesic days at erenumab initiation 2 6 6 20 7 4 12 8.1 (6.1)
HIT-6 score at erenumab initiation 68 65 70 75 66 68 63 67.9 (3.9)
Frisén grade at erenumab initiation (both eyes) 0 0 0 0 0 0 0 0
OCT global average RNFL thickness at Erenumab initiation worst eye (μm) c 118 93 123 113 107 118 103 110.7
(10.4)
BMI at erenumab initiation 31 46.2 35.2 37.3 42.1 29.4 28.8 35.7 (6.6)




D, T B, T
Acetazolamide at erenumab initiation no no no no no 500
mg
no
Patient clinical characteristics at erenumab initiation. Monthly values refer to the 30-day pre-treatment period. *, p values indicate changes from the 30-day pre-
treatment period prior to erenumab initiation
aFailure defined as any of: inadequate efficacy with appropriate dosing and treatment duration; intolerable adverse effects; contraindications preventing use
bTrial defined as any of: inadequate efficacy with appropriate dosing and treatment duration; intolerable adverse effects
cHeidelberg Engineering SPECTRALIS, Heidelberg, Germany
+++ severe
Abbreviations: P Patient, IIH Idiopathic intracranial hypertension, MmsHD Monthly moderate/severe headache days, MHD Monthly headache days, NRS Numeric
Rating Scale (0 = no pain to 10 = worst imaginable pain), HIT-6 Headache impact test-6, BMI Body mass index, B Blurred vision, D double vision, T Tinnitus, V Visual
obscurations, OCT Optical coherence tomography, RNFL Retinal nerve fiber layer
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depression and pizotifen due to the risk of weight gain)
and erenumab was commenced. Headaches substantially
improved (Table 2), but she developed visual disturbances
(obscurations) and was noted to have recurrent active
papilloedema. She was commenced on acetazolamide and
advised to lose weight. Headaches remained improved
(Table 2) despite return of papilloedema.
Case 4
A 24 year old woman first presented with worsening
headaches and visual disturbances and was noted to
have papilloedema with a BMI of 38 kg/m2. The head-
aches had a migraine-like phenotype. She had a history
of occasional tension type headaches, bipolar disorder
and no family history of migraines. With no alternative
cause of raised ICP on brain imaging (MRI Head and
MR Venogram) an LP was performed revealing an
opening pressure of 40 cm CSF and a diagnosis of IIH
was made [6]. She had further LPs with similar opening
pressures in the short term with no sustained headache
improvement and was commenced on acetazolamide. At
subsequent review her papilloedema was in remission
and she had already stopped her acetazolamide due to
side effects. She was, however, still suffering with on-
going disabling chronic migraine-like headaches for over
12 months since IIH diagnosis. Due to risk of deteriorat-
ing mood and weight gain topiramate and tricyclics/
beta-blockers were contraindicated, respectively. Cande-
sartan was also contraindicated due to postural vaso-
vagal episodes and she was commenced on erenumab.
Her headaches substantially improved (Table 2). Subse-
quently, visual obscurations returned and she was noted
to have a relapse of her papilloedema whilst still main-
taining the improvement in her headaches. She was
Table 2 Patient clinical outcomes
P1 P2 P3 P4 P5 P6 P7 Mean (SD)
MmsHD change at 3 months − 3 − 6 − 9 − 9 − 2 − 6 − 4 − 5.6 (2.8)
p = 0.002
MmsHD change at relapse − 5 − 13 − 6 − 13 − 7 − 10 − 6 −8.6 (3.4)
p < 0.001
MHD change at 3 months − 20 0 − 18 − 12 − 15 −16 − 4 −12.1 (7.4)
p = 0.028
MHD change at relapse − 22 0 0 −15 − 10 − 24 − 5 − 10.9 (9.9)
p = 0.043
Headache severity (NRS) change at 3 months 2 −0.9 0.2 −2.6 0.1 0.1 −1.7 −0.4 (1.5)
p = 0.497
Headache severity (NRS) change at relapse 2.7 −1.4 −0.8 −2.7 − 1.8 − 0.4 −2.4 − 1.0 (1.8)
p = 0.253
Monthly analgesic days change at 3 months 3 −1 − 6 − 18 0 − 4 −9 − 5.0 (7.0)
p = 0.107
Monthly analgesic days change at relapse 0 0 −5 −18 −7 1 −10 −5.6 (6.9)
p = 0.075
HIT-6 score change at 3 months − 5 −11 − 4 − 13 1 − 8 2 − 5.4 (5.7)
p = 0.045
HIT-6 score change at relapse − 5 − 13 −4 −3 0 −18 − 2 −6.4 (6.6)
p = 0.041
Frisén grade at relapse (worst eye) 4 2 3 1 1 1 1 1.9 (1.2)
OCT global average RNFL thickness at relapse worst eye (μm) a 326 b 140 b 174 b 132 c 116 c 151 c 202 c 177.3 (71.4)
p = 0.043
BMI at relapse 31.3 48.5 38.7 38 44.6 36.7 30.5 38.3 (6.5)
p = 0.025
BMI change 0.3 2.3 3.5 0.7 2.5 7.3 1.7 2.6 (2.3)
IIH characteristics at relapse B, T, V B, T B, T, V B, D, T B, D, T B, D, T B, T
Side effects CO HT, I I CO, MC
Clinical outcomes and changes compared to erenumab initiation and the 30-day pre-treatment period *, p values indicate changes from erenumab initiation and
the 30-day pre-treatment period
aHeidelberg Engineering SPECTRALIS, Heidelberg, Germany
bAt 6months since commencing erenumab
cAt 12 months since commencing erenumab
Abbreviations: P Patient, IIH Idiopathic intracranial hypertension, MmsHD Monthly moderate/severe days, MHD Monthly headache days, NRS Numeric Rating Scale
(0 = no pain to 10 = worst imaginable pain), HIT-6 Headache impact test-6, BMI Body mass index, B Blurred vision, D Double vision, T Tinnitus, V Visual
obscurations, OCT Optical coherence tomography, RNFL Retinal nerve fiber layer, CO Constipation, HT Hair thinning, I Itch, MC Muscle cramps
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offered acetazolamide, advised to lose weight and her
papilloedema did not worsen. Her headaches remained
in remission during the IIH recurrence.
Case 5
A 36 year old woman, with a BMI of 41 kg/m2, initially
presented with debilitating headaches, tinnitus and visual
disturbances. The optometrist noted papilloedema.
Headaches had a migraine-like phenotype. She had a
past medical history of low mood, familial structural
renal tract abnormalities and no family history or prior
history of migraines. Following normal neuro-imaging,
CT Head and CT venogram (apart from radiological
signs of raised ICP), an LP was performed with an
Fig. 1 Headache days, BMI and optical coherence testing of patients. a Monthly moderate/severe headache days (MmsHD) at clinical assessment
time-points. Each patient is represented by different colour. Relapse point is represented by empty circle or triangle large point for each patient.
b Mean number of monthly moderate/severe headache days (MmsHD) and total monthly headache days (MHD) at − 12 months, erenumab
initiation (0 months), 3 months and at relapse. Error bars represent standard error of the mean (SEM). T-test performed for changes compared to
erenumab initiation for MmsHD and Wilcoxon signed ranks test performed for changes compared to erenumab initiation for MHD. ***P < 0.001
compared to erenumab initiation, ** P < 0.01 compared to Erenumab initiation, * P < 0.05 compared to Erenumab initiation. c Body mass index
percentage change at time of relapse compared to erenumab initiation (substantial fluctuations in weight were possible in between formal
clinical assessments, but were not measured). Each patient is represented by different colour. d Optical coherence tomography (OCT) global
average peripapillary retinal nerve fibre layer (pRNFL) thickness at clinical assessment time-points (0 months represents erenumab initiation time-
point). Each patient is represented by different colour. e Infrared image of the right eye at erenumab initiation (Heidelberg Engineering SPECTRAL
IS, Heidelberg, Germany) for Patient 2 (P2). This shows no papilloedema. f Infrared image of the right eye at 6 months Patient 2 (P2). This shows
recurrence of papilloedema. g Graph of OCT cross-sectional pRNFL thickness derived from 12° ring scan centred on the optic disc (Heidelberg
Engineering SPECTRALIS, Heidelberg, Germany) for Patient 2 (P2). Black line shows the cross-sectional pRNFL thickness of the six-month scan
(relapse), with the grey line showing the same information for the erenumab initiation scan. The difference between these lines (red arrows)
indicates the magnitude of increase in pRNFL thickness between these scans, demonstrating relapse of IIH and recurrence of active
papilloedema. The shaded green area indicates the proprietary ‘normal’ range for pRNFL thickness. Abbreviations: MmsHD, Monthly moderate/
severe headache days; MHD, Monthly headache days; OCT, Optical coherence testing; RNFL, retinal nerve fibre layer; TMP, Temporal; SUP,
Superior; NAS, Nasal; INF, Inferior
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opening pressure recorded at 37 cm CSF. A diagnosis of
IIH was given [6] and due to the risk of renal impair-
ment acetazolamide was not recommended and she was
referred to a community weight management program
which successfully helped her reduce her BMI to 30 kg/
m2 with concurrent resolution of her papilloedema. Her
chronic migraine-like headaches persisted over 12
months despite therapeutic trials of amitriptyline, topira-
mate, dosulepin and candesartan with inadequate effi-
cacy or intolerable side effects. She was commenced on
erenumab with a marked improvement in headaches
(Table 2). Unfortunately her weight increased (to a BMI
42 kg/m2) and her papilloedema recurred. However, her
headaches did not increase as they previously have when
she initially presented with IIH (Table 2). She was again
referred to a community weight management program
which was successful in helping her reduce her weight
and her papilloedema improved.
Case 6
A 25 year old woman originally presented with marked
worsening of headaches and tinnitus, papilloedema was
noted. Her BMI was 35 kg/m2. The headache phenotype
was migraine-like. She had a past history of episodic mi-
graines, hypermobility, back pain, Raynaud’s syndrome,
depression, low vitamin D and family history of mi-
graines. No alternative cause of raised ICP was found on
brain imaging (MRI Head and MR Venogram) and an
LP was performed with an opening pressure of 35 cm
CSF and the diagnosis of IIH was made [6]. She was
given advice on weight loss and commenced on acet-
azolamide. Following successful weight loss her papilloe-
dema resolved despite persistence of her chronic
migraine-like headaches over 12 months. Due to reso-
lution of papilloedema and associated side effects, acet-
azolamide was stopped. She had tried duloxetine for low
mood with no effect on her persistent headaches. Due to
risk of deteriorating mood and weight gain topiramate
and tricyclics/beta-blockers were contraindicated, re-
spectively and was commenced on erenumab. Headaches
improved on erenumab (Table 2) but she then developed
increasing blurred vision in the context of weight gain.
On examination a relapse of papilloedema was noted.
Acetazolamide was commenced and weight loss advice
was provided. The headaches remained controlled
throughout the IIH relapse.
Case 7
A 25 year old woman (BMI of 31 kg/m2) presented with
disabling increasing headaches and papilloedema was
noted. The headaches had a migraine-like phenotype. She
did not have any significant past medical history and no
family history of migraines. Neuro-imaging (MRI Head
and MR Venogram) did not reveal an alternative cause of
raised ICP and an LP recorded an opening pressure of 54
cm CSF (followed by post-LP headache exacerbation for 1
week). A diagnosis of IIH was made [6]. She was com-
menced on acetazolamide and advised to lose weight. Nei-
ther acetazolamide nor topiramate were tolerated and did
not improve her chronic migraine-like headaches that
remained over 12months. Following weight loss, the
papilloedema resolved but migraine-like headaches per-
sisted. Due to risk of weight gain, tricyclics and beta-
blockers were contraindicated and erenumab was initiated
which improved her headaches (Table 2). At follow-up
weight gain was noted and clinical examination revealed
return of papilloedema. She was commenced on acetazol-
amide and advised to lose weight. Papilloedema subse-
quently improved. Her headaches remained controlled on
erenumab despite the IIH relapse.
Summary results
We have reported seven patients with IIH who had dis-
abling long term headaches with migraine-like character-
istics (mean (SD) IIH duration 2.4 (1.4) years) persisting
despite complete resolution of papilloedema. Monthly
headache burden was significantly reduced following ini-
tiation of a CGRP monoclonal antibody therapy
(Table 2). Of principle interest here is the lack of head-
ache symptoms when raised ICP retuned, as evidenced
by recurrent papilloedema, whist they were taking the
CGRP monoclonal antibody, despite headache being the
dominant feature at initial IIH presentation and indicat-
ing exacerbations of IIH in the past. The relapse of IIH
was identified at follow up due to patients’ describing
minimal or subjective changes in IIH symptoms (blurred
vision, double vision, transient visual obscurations, tin-
nitus) or weight gain (Table 1) which prompted slit-
lamp examination and OCT imaging, which confirmed
the recurrence of papilloedema (Table 2, Fig. 1). Im-
proved headache burden was also noted at subsequent
time points despite ongoing papilloedema (Fig. 1). Ere-
numab reduced the mean frequency of MmsHD by 38%
at 3 months, 49% at 6 months, 63% at 9 months and 65%
at 12 months compared to the 30-day pre-treatment
period. There was a reduction in mean frequency in
overall MHDs by 45% at 3 months, 30% at 6 months,
50% at 9 months and 42% at 12 months. There were no
serious side effects of treatment reported at the 3-
monthly assessments (over 12 months) and none of the
patients withdrew from erenumab.
Discussion
Erenumab significantly reduced the mean frequency of
MmsHD at the 3-monthly time-points up to 12months
compared to the 30-day pre-treatment period, with cor-
responding significant reductions in the total MHD and
HIT-6 score, despite the recurrence of active IIH and
Yiangou et al. The Journal of Headache and Pain          (2020) 21:116 Page 6 of 8
relapse of papilloedema (Table 2). Whilst spontaneous
fluctuation in headaches are well described, we suggest
that the improvements noted in these subjects are un-
likely to represent a fluctuating disease course as the
headaches had been stable and severe (for at least 12
months) prior to initiation of Erenumab and then
showed sustained improvement (over the forthcoming
12months) after starting erenumab.
The mechanisms driving headache in patients with IIH
have not been elucidated and treatment approaches have
no evidence basis [1, 4, 5]. Headaches in IIH are typically
chronic migraine-like, drive disability, and are a patient
prioritised key area for mechanistic research and treat-
ment [3–5]. CGRP is a key modulator of migraine head-
aches [9] and this case series suggests evidence for the
role of CGRP as an important nociceptive stimulus in IIH
headaches. Four out of seven patients had a pre-existing
migraine diagnosis. However all patients presented with a
severe headache exacerbation at the initial presentation of
IIH, indicating that their headaches exacerbation were
temporarily linked with raised ICP and fulfilled the Inter-
national Classification of Headache Disorders diagnostic
criteria 3b for IIH headache [10]. Following ocular remis-
sion, headaches persisted (as frequently occurs in IIH)
[11] and were successfully treated as chronic migraine-like
headaches with erenumab (after ≥3 prior conventional
oral preventative treatment failures). In these patients, in
whom headache has been the presenting symptom indi-
cating elevated ICP at diagnosis, erenumab effectively con-
trolled headaches even when IIH relapsed with return of
papilloedema. In the 4 patients with pre-existing migraine
we can’t exclude that in these subjects’ headaches were
driven by co-morbid migraine.
The therapeutic reduction of headache was noted in
IIH patients in ocular remission, but more importantly
also during the subsequent phase of recurrent active
IIH, suggesting that headaches driven by raised ICP may
involve CGRP release.
Exacerbation of headache is a common trigger for IIH
patients to seek medical review, typically indicated recur-
rence of IIH and papilloedema. However, development of
active papilloedema in this series of IIH patients treated
with a CGRP monoclonal antibody was not associated
with exacerbation of headache. Whilst the enduring con-
trol of headaches, even during a period of actively elevated
ICP with papilloedema, is symptomatically advantageous
to the patients there is also an important caution. In these
cases, the headaches were controlled and did not recur to
warn of an IIH disease relapse hence there could be a risk
that relapse of IIH could be missed. Funduscopic review is
typically reduced in frequency in IIH patients in whom
IIH has resolved (typical follow up intervals recommended
in the IIH guidelines) [1]. But in IIH patients who respond
to CGRP monoclonal antibody therapy for headache, we
would recommend ongoing regular fundoscopy, with a
low threshold for a complete neuro-ophthalmic assess-
ment and pharmacovigilance monitoring as recurrence of
headache may not occur to warn of an IIH relapse. In
these cases, mild subjective changes in IIH symptoms and
weight gain were markers of IIH relapse (in the absence of
headache recurrence). It is important not to miss recur-
rence of papilloedema, as patients require visual function
monitoring and management to mitigate the risk of visual
loss [6]. In the setting of known IIH we feel it is unlikely
that the papilloedema was attributed to the erenumab
treatment itself, but this cannot be excluded.
These cases may provide the first insight that CGRP
may be a key mechanistic driver for IIH headaches when
raised ICP is present, manifesting as papilloedema. Head-
ache therapies are a patient priority and an unmet need in
IIH with no previous trials of headache preventative ther-
apies in IIH [5]. CGRP may represent a therapeutic target
for raised ICP IIH headaches and clinical trials investigat-
ing CGRP-specific agents would be of interest.
Clinical implications
 CGRP monoclonal antibodies successfully treat
resistant chronic migraine-like headaches in those
with IIH in whom their papilloedema had resolved.
 CGRP may have a mechanistic role in driving raised
ICP headaches in active IIH.
 The therapeutic potential of CGRP monoclonal
antibodies for IIH headache warrants further
evaluation in a clinical trial.
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